<SEC-DOCUMENT>0001104659-25-014310-index.html : 20250214 <SEC-HEADER>0001104659-25-014310.hdr.sgml : 20250214 <ACCEPTANCE-DATETIME>20250214171351 ACCESSION NUMBER: 0001104659-25-014310 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 18 FILED AS OF DATE: 20250214 DATE AS OF CHANGE: 20250214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-283900 FILM NUMBER: 25630863 BUSINESS ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 </SEC-HEADER> <DOCUMENT> <TYPE>424B3 <SEQUENCE>1 <FILENAME>tm2430195-17_424b3.htm <DESCRIPTION>424B3 <TEXT> Document 1 - file: tm2430195-17_424b3.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>2 <FILENAME>lg_caratmtherap-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 2 - file: lg_caratmtherap-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>3 <FILENAME>fc_pipeline-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 3 - file: fc_pipeline-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>4 <FILENAME>fc_canonical-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 4 - file: fc_canonical-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>5 <FILENAME>fc_dualmechanism-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 5 - file: fc_dualmechanism-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>fc_centralcatalyst-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 6 - file: fc_centralcatalyst-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>fc_currentpipeline-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 7 - file: fc_currentpipeline-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>8 <FILENAME>fc_ipfaffected-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 8 - file: fc_ipfaffected-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>9 <FILENAME>fc_lungfibrosis-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 9 - file: fc_lungfibrosis-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>10 <FILENAME>bc_bothextrinsic-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 10 - file: bc_bothextrinsic-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>11 <FILENAME>bc_dosedepen-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 11 - file: bc_dosedepen-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>12 <FILENAME>fc_evaluating-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 12 - file: fc_evaluating-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>13 <FILENAME>fc_mousemodel-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 13 - file: fc_mousemodel-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>14 <FILENAME>fc_engrafted-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 14 - file: fc_engrafted-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>15 <FILENAME>lc_treatment-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 15 - file: lc_treatment-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>16 <FILENAME>fc_clinicaltrial-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 16 - file: fc_clinicaltrial-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>17 <FILENAME>px_25caraproxy1pg01-bw.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 17 - file: px_25caraproxy1pg01-bw.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>18 <FILENAME>px_25caraproxy1pg02-bw.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 18 - file: px_25caraproxy1pg02-bw.jpg
</DOCUMENT> </SEC-DOCUMENT>